Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Downloads
Exports from our negotiations database are available for download in CSV or JSON formats.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
SIR-Spheres Y-90 resin microspheres (Yttrium-90 microspheres)
Status:
Concluded with an LOI
Manufacturer:
Sirtex Medical
Indication:
Hepatocellular carcinoma (HCC)
Last updated:
August 14, 2024
Opdualag (nivolumab and relatlimab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Unresectable or metastatic melanoma in adult and pediatric patients 12 years of age or older who have not received prior systemic therapy for unresectable or metastatic melanoma
Last updated:
August 8, 2024
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)
Last updated:
July 31, 2024
Lonsurf (trifluridine/tipiracil)
Status:
Concluded with an LOI
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Metastatic colorectal cancer in adult patients who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents. ( in combination with bevacizumab)
Last updated:
July 29, 2024
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy, in adult patients
Last updated:
July 22, 2024